{‘She lacks little experience’: the US healthcare field braces for Dr. Høeg's tenure at the FDA.
As the United States continues making historic revisions to its vaccine schedules, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on Covid shots during the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).
Planned Changes to Childhood Immunization Program
Public health authorities had intended to reveal major changes to the childhood vaccination calendar recently, aligning the US with the Danish vaccine program, it is understood – a substantial departure that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. This reveal has been delayed until the new year.
In place of the top vaccines chief, Høeg is scheduled to speak at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.
Consolidating Power at the Agency
Høeg's temporary position could signify a strengthened alliance between the drug and biologics centers as Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon dismantling previously authorized immunizations at the FDA.
Dr. Høeg has often pushed for discontinuing some pediatric shot schedules in the US to become more like the Danish model, a nation with nationalized medicine and a population approximately the size of the state of Wisconsin.
To date public appearances, she has continued to focus on vaccines – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.
Concerns Over Qualifications
Dr. Høeg has little discernible track record in pharmaceutical research, approval processes or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since spring.
“She appears not to have any of the qualifications” for running the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a major agency. She lacks background in drug approvals.”
Past commissioners of the center would “grasp legal statutes and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who headed the center have had.”
This division has an vast workload at the FDA, the former commissioner emphasized.
“Everybody just pays attention on the new drug program, but the generic drug division authorizes thousands of generic medications. There is also a biosimilars program, OTC medication office and more, and all of those need to be looked after,” she explained. “The area you neglect, that is precisely what that I always told people is going to bite you.”
Furthermore, a major leadership component to the job, which manages over 5,000 employees. “It’s a enormous management job, if you execute it properly,” she added.
Agency Reaction and Disputed Initiatives
Regarding concerns about Dr. Høeg's fitness for the role and whether this assignment represents increased cooperation among agency officials on immunizations, a representative said that the “concerns rely on incorrect presumptions”.
“Her resume matches the responsibilities of her position,” the spokesperson said, citing the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.
In her interim role, Høeg takes over the agency head's controversial expedited review system, a controversial expedited medication authorization process that allegedly concerned her former heads. “How are these therapies being picked for this expedited pathway? Who takes the calls?” Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”
Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards less stringent oversight of most medications, except for immunizations.”
Public History on Immunizations
Concerning immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard observe. She authored a study using unverified public submissions to estimate the incidence of myocarditis following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are riskier than they are.
Among her “desired changes” for the current government included changing regulations for recently developed shots and ending “non-essential” immunizations, she said post-election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of excluding young men from receiving Covid vaccines.
“She is an all-around ideologue who commences with her beliefs and tailors the evidence to fit the data in a highly disingenuous, dishonest way,” Howard said.
Taking Control and a “Campaign of Retribution”
Dr. Høeg became part of other dissenters, {like|